Novartis receives FDA approval for Cosentyx label update
Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat…
Read More...
Read More...